Aardvark Therapeutics Financials - Benzinga

Aardvark Therapeutics Inc

AARDNASDAQ

Trade with Public

Trade with Public

$5.66

0.519.9%

Last update: Sep 17, 10:38 AM

Overview News Earnings Forecast Events Price TargetsFinancialsSentiment Ownership Compare Options Stock Report

Aardvark Therapeutics Financials

Aardvark Therapeutics (AARD) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Aardvark Therapeutics Q2 EPS $(0.66) Beats $(0.91) Estimate

Aardvark Therapeutics (NASDAQ:AARD) reported quarterly losses of $(0.66) per share which beat the analyst consensus estimate of $(0.91) by 27.47 percent. This is unchanged from the same period last year.

Benzinga Newsdesk

PRO
Aardvark Therapeutics Q1 EPS $(0.99) Misses $(0.90) Estimate

Aardvark Therapeutics (NASDAQ:AARD) reported quarterly losses of $(0.99) per share which missed the analyst consensus estimate of $(0.90) by 10 percent. This is a 39.44 percent decrease over losses of $(0.71) per share

Benzinga Newsdesk

PRO
Aardvark Therapeutics Q4 EPS $(0.81) Beats $(0.91) Estimate

Aardvark Therapeutics (NASDAQ:AARD) reported quarterly losses of $(0.81) per share which beat the analyst consensus estimate of $(0.91) by 11.09 percent. This is a 62.5 percent increase over losses of $(2.16) per share

Benzinga Newsdesk

Stock Market Today: S&P 500, Dow Jones Futures Slide Amid War Against Iran— AMTD Digital, Aardvark, MongoDB In Focus

U.S. stock futures fell sharply on Monday following Friday’s losses. Futures of the major benchmark indices were negative amid the ongoing Iran-U.S. conflict.

Rishabh Mishra

PRO
Aardvark Therapeutics Q3 EPS $(0.75) Beats $(0.80) Estimate

Aardvark Therapeutics (NASDAQ:AARD) reported quarterly losses of $(0.75) per share which beat the analyst consensus estimate of $(0.80) by 6.72 percent. This is a 28.57 percent increase over losses of $(1.05) per share

Benzinga Newsdesk

PRO
Aardvark Therapeutics Q2 EPS $(0.66) Misses $(0.61) Estimate

Aardvark Therapeutics (NASDAQ:AARD) reported quarterly losses of $(0.66) per share which missed the analyst consensus estimate of $(0.61) by 7.67 percent. This is a 51.82 percent increase over losses of $(1.37) per share

Benzinga Newsdesk